Prognostic Significance of the Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Patients with Stage III and IV Colorectal Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2017 Feb 18

PMID 28210087

Citations 44

Authors

Jae Hyun Kim

Jun Yeop Lee

Hae Koo Kim

Jin Wook Lee

Sung Gyu Jung

Kyoungwon Jung

Sung Eun Kim

Won Moon

Moo In Park

Seun Ja Park

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with colorectal cancer (CRC).

Methods: Between April 1996 and December 2010, medical records from a total of 1868 patients with CRC were retrospectively reviewed. The values of simple inflammatory markers including NLR and PLR in predicting the long-term outcomes of these patients were evaluated using Kaplan-Meier curves and Cox regression models.

Results: The median follow-up duration was 46 mo (interquartile range, 22-73). The estimation of NLR and PLR was based on the time of diagnosis. In multivariate Cox regression analysis, high NLR (≥ 3.0) and high PLR (≥ 160) were independent risk factors predicting poor long-term outcomes in patients with stage III and IV CRC. However, high NLR and high PLR were not prognostic factors in patients with stage I and II CRC.

Conclusion: In this study, we identified that high NLR (≥ 3.0) and high PLR (≥ 160) are useful prognostic factors to predict long-term outcomes in patients with stage III and IV CRC.

Citing Articles

Prognostic value of routine blood biomarkers in 3-year survival of resectable colorectal cancer patients: a prognostic nomogram for clinical practice.

Moro-Valdezate D, Martin-Arevalo J, Cozar-Lozano C, Garcia-Botello S, Perez-Santiago L, Casado-Rodrigo D Int J Colorectal Dis. 2025; 40(1):58.

PMID: 40045061 PMC: 11882633. DOI: 10.1007/s00384-025-04848-3.

Relationship Between Systemic Inflammatory Response Exponents, Levels of ADAM10, ADAM17 Proteins and Selected Clinical Parameters in Patients with Colorectal Cancer: Original Research Study.

Sikora-Skrabaka M, Walkiewicz K, Waniczek D, Strzelczyk J, Nowakowska-Zajdel E Int J Mol Sci. 2025; 26(3).

PMID: 39940871 PMC: 11817235. DOI: 10.3390/ijms26031104.

The prognostic value of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in colorectal cancer and colorectal anastomotic leakage patients: a retrospective study.

Xu N, Zhang J, Zhang J, Huang Z, Mao L, Zhang Z BMC Surg. 2025; 25(1):57.

PMID: 39910526 PMC: 11796187. DOI: 10.1186/s12893-024-02708-5.

Combined inflammation-related biomarkers and clinicopathological features for the prognosis of stage II/III colorectal cancer by machine learning.

Liang L, Xu N, Ding L, Li X, Jiang C, Zhang J BMC Cancer. 2024; 24(1):1548.

PMID: 39696042 PMC: 11656819. DOI: 10.1186/s12885-024-13331-1.

Clinical significance of the modified Naples prognostic score in patients with stage II-III colon cancer undergoing curative resection: a retrospective study from the real world.

Li X, Cheng C, Huo X, Zhao C, Yuan H, Chen G Front Oncol. 2024; 14:1403666.

PMID: 39351349 PMC: 11439623. DOI: 10.3389/fonc.2024.1403666.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Neofytou K, Smyth E, Giakoustidis A, Khan A, Cunningham D, Mudan S . Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol. 2014; 31(10):239. DOI: 10.1007/s12032-014-0239-6. View

Absenger G, Szkandera J, Stotz M, Postlmayr U, Pichler M, Ress A . Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Anticancer Res. 2013; 33(10):4591-4. View

Malietzis G, Giacometti M, Kennedy R, Athanasiou T, Aziz O, Jenkins J . The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: a systematic review and meta-analysis. Ann Surg Oncol. 2014; 21(12):3938-46. DOI: 10.1245/s10434-014-3815-2. View

Yamaguchi K, Ogata Y, Akagi Y, Shirouzu K . Identification of high-risk factors as indicators for adjuvant therapy in stage II colon cancer patients treated at a single institution. Oncol Lett. 2013; 6(3):659-666. PMC: 3789105. DOI: 10.3892/ol.2013.1433. View

Jess T, Rungoe C, Peyrin-Biroulet L . Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012; 10(6):639-45. DOI: 10.1016/j.cgh.2012.01.010. View

Morris M, Platell C, de Boer B, McCaul K, Iacopetta B . Population-based study of prognostic factors in stage II colonic cancer. Br J Surg. 2006; 93(7):866-71. DOI: 10.1002/bjs.5345. View

Roth A, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D . Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2009; 28(3):466-74. DOI: 10.1200/JCO.2009.23.3452. View

Pathak S, Nunes Q, Daniels I, Smart N . Is C-reactive protein useful in prognostication for colorectal cancer? A systematic review. Colorectal Dis. 2014; 16(10):769-76. DOI: 10.1111/codi.12700. View

10.

Hung H, Chen J, Yeh C, Changchien C, Tang R, Hsieh P . Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis. 2011; 26(8):1059-65. DOI: 10.1007/s00384-011-1192-x. View

11.

Zou Z, Liu H, Ning N, Li S, Du X, Li R . Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett. 2016; 11(3):2241-2248. PMC: 4774601. DOI: 10.3892/ol.2016.4216. View

12.

Chua W, Charles K, Baracos V, Clarke S . Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011; 104(8):1288-95. PMC: 3078587. DOI: 10.1038/bjc.2011.100. View

13.

Chang Z, Zheng J, Ma Y, Zhao J, Wang C, Liu Z . The neutrophil-to-lymphocyte ratio as a predictor for recurrence of colorectal liver metastases following radiofrequency ablation. Med Oncol. 2014; 31(3):855. DOI: 10.1007/s12032-014-0855-1. View

14.

Pichler M, Hutterer G, Stoeckigt C, Chromecki T, Stojakovic T, Golbeck S . Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013; 108(4):901-7. PMC: 3590665. DOI: 10.1038/bjc.2013.28. View

15.

Szkandera J, Pichler M, Absenger G, Stotz M, Arminger F, Weissmueller M . The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg. 2014; 208(2):210-4. DOI: 10.1016/j.amjsurg.2013.10.030. View

16.

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

17.

Lee Y, Choi C, Kim H, Kim T, Lee J, Lee J . Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res. 2012; 32(4):1555-61. View

18.

Chan A, Ogino S, Fuchs C . Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007; 356(21):2131-42. DOI: 10.1056/NEJMoa067208. View

19.

Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C . Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2010; 29(1):17-24. DOI: 10.1200/JCO.2010.30.1077. View

20.

Goubran H, Stakiw J, Radosevic M, Burnouf T . Platelets effects on tumor growth. Semin Oncol. 2014; 41(3):359-69. DOI: 10.1053/j.seminoncol.2014.04.006. View